Dario Trapani, Medical Oncologist at European Institute of Oncology (IEO), Researcher at Department of Oncology and Hemato-Oncology at University of Milan, shared Francesco Schettini, Physician scientist at the Breast Unit of the Hospital Clinic of Barcelona and IDIBAPS, on LinkedIn, adding:
“SONIA trial has reshaped the way we (statistically) may approach clinical trial design, based on value metrics (ESMO – European Society for Medical Oncology MCBS) and providing the first modern paradigm to shape therapeutic sequencing in real-life. A universal scenario in oncology.
Under a bayesian re-reading, well, this trial may inform clinical practice.
In the current treatment landscape of mBC HR+/HER2-, it might intersect many patients for whom such an option could be considered – as next lines are biomarker informed in about 30% of pts, leaving most of the debate in this specific setting still deemed for re-consideration. Hope to see some real-life and patients’ journey studies – in the way Marilina Piccirillo is doing in her research. Whether data from SONIA are reconfirmed in practice, this is a true opportunity!
Times for value vs health system considerations under the lens of implementation science and sobriety to come.
Quoting Francesco Schettini, Physician scientist at the Breast Unit of the Hospital Clinic of Barcelona and IDIBAPS, on LinkedIn:
“First-line CDK4/6i+ET in the SONIA trial did not improve OS vs second-line CDK4/6i+ET, though in a subgroup analysis with positive interaction, premenopausal patients did gain an OS benefit by upfront use of the combination. Interesting result.”
Title: Overall Survival With First-Line vs Second-Line CDK4/6 Inhibitor Use in Advanced Breast Cancer
Authors: Noor Wortelboer, Annemiek van Ommen-Nijhof, Inge R. Konings.
Other articles featuring Dario Trapani and Francesco Schettini on OncoDaily.